New-generation mealtime insulin approved in Europe

Novo Nordisk to launch Fiasp in first half of 2017.

The European Commission has granted marketing authorisation for Novo Nordisk's Fiasp for the treatment of diabetes in adults. The authorisation covers all 28 European Union member states.

Fiasp is the brand name for fast-acting insulin aspart. Fiasp provides improved mealtime and overall glucose control with a similar safety profile versus NovoRapid.

"Fiasp is a new-generation mealtime insulin; it is an innovative faster formulation of insulin aspart that more closely mimics the physiological insulin response around meals. The incremental benefits with Fiasp are comparable to those observed for the last generation of mealtime insulins when introduced more than a decade ago," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.

Fiasp will be available in vial, Penfill and FlexTouch pen.

Novo Nordisk expects to launch Fiasp in the first European countries in the first half of 2017.